Deep Track Capital, based in Greenwich, Connecticut, is a distinguished investment firm specializing in the vibrant life sciences sector. They are dedicated to cultivating enduring partnerships with forward-thinking management teams within leading public and pre-IPO biotechnology firms. In addition to providing financial backing, Deep Track Capital offers its wealth of experience and expertise, actively engaging with partners to drive innovation and growth. Leveraging their extensive network, they foster mutually beneficial connections aimed at achieving shared success. Deep Track Capital excels in leading transformative transactions, and orchestrating robust syndicates to amplify impact. Moreover, they eagerly participate in investment rounds spearheaded by reputable investors, recognizing the strength of collaborative investment approaches.
Mr. David E. Kroin, Founder & Chief Investment Officer at Deep Track Capital LP, brings over 23 years of extensive investment expertise to the healthcare sector. He serves on the Board of Directors at CorEvitas LLC, demonstrating his commitment to advancing healthcare innovation and excellence. Before establishing Deep Track Capital, David co-founded Great Point Partners in 2003, where he played a pivotal role as the co-portfolio manager for its equity long/short biotechnology hedge fund. Additionally, he served as an esteemed investment committee member for Great Point's private equity funds, specializing in the strategic investment in healthcare companies through recaps and buyouts. David Kroin holds a Bachelor of Science in Actuarial Mathematics from the University of Michigan and actively contributes to the University's Life Sciences Institute as a member of its leadership council. His profound industry insights and strategic acumen have led him to serve on numerous boards of both public and private healthcare companies, including CellCarta, Cytovance, Mediatech, ProPT, Biodel, APT, Gentium, and US Bioservices.
Deep Track Capital manages discretionary assets totaling $5,116,080,002, as reported in their Form ADV dated March 2024. Their most recent 13F filing for the fourth quarter of 2023 revealed $2,994,349,040 in managed 13F securities, with a significant concentration of 40.51% among their top 10 holdings. Among their notable holdings, Deep Track Capital's largest position is in Insmed Inc., with a substantial holding of 5,350,000 shares.
